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dated. Overall, 16 (39%) of studies detected a statisti-
cally significant HRQoL difference associated with any
prostate cancer treatment, 6 (37.5%) of which are single-
treatment studies with pre-post designs, 10 (62.5%) of
which are between-treatment studies. 
CONCLUSIONS: Selection of appropriate HRQoL-max-
imizing therapies for prostate cancer patients requires in-
formation on competing alternatives. Currently, the liter-
ature does not adequately address this need. Generic
measures have not been responsive to treatment-related
changes in HRQoL for prostate cancer. More work is
needed to develop sensitive and externally valid measures of
the multiple approaches to treating prostate cancer.
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OBJECTIVE: Little has been reported on the frequency
of complementary and alternative medicine (CAM) treat-
ments among prostate cancer (PCa) patients despite
growing use in other conditions. This research reports on
utilization of CAM treatments among a group of recently
diagnosed PCa patients. 
METHODS: We identified a cohort of 995 newly diag-
nosed PCa patients enrolled in CaPSURE, a longitudinal
observational database. Patients report on the use of
CAM treatments in quarterly, self-administered question-
naires. Patients indicate whether or not they have used
CAM and then indicate the specific treatment. Chiro-
practic visits are not considered an alternative therapy in
this database. 
RESULTS: Mean age of patients was 75.9 years. Patients
were 71% white and 11% African American, 44% had
some college, median income was $30,000. Median fol-
low-up was 12 months. CAM treatment was reported by
36.4% of patients. The most frequently reported CAM
treatments were: 1) herbal medicine (including Chinese
herbs, other herbs, saw palmetto, and St. John’s Wort),
19.2%; 2) diet, nutrition, and lifestyle modification (such
as smoking cessation or exercise), 9.7%; 3) vitamins/min-
erals, 8.3%; 4) acupuncture, 4.9%; 5) homeopathic reme-
dies, 3.1%; 6) meditation and biofeedback, 1.8%. Other
treatments included: massage/bodywork, immune enhanc-
ers, hypnotherapy, and miscellaneous items such as pet
adoption. 
CONCLUSIONS: We found that a significant proportion
of newly diagnosed PCa patients (36%) reported use of
CAM treatments. These results are similar to data re-
ported for other chronic conditions, such as arthritis,
HIV-infection, and other cancers where 30–60% of pa-
tients report use of CAM therapies. Further research into
the benefit of these therapies in terms of improved pa-
tient functioning is needed.
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Current literature suggests that nearly 18% of lifetime
costs for medical care ($40,000 per person) is estimated
to be incurred in the last year of life and nearly 28% of
US Medicare payments for those over age 65 are for per-
sons in their last year of life (Scitoversusky 1994). Little
has been reported, however, on total medical costs at the
end-of-life for prostate cancer (PCa) patients. 
OBJECTIVE: The aim of this research was to compare
the last year of medical costs in PCa patients dying at
home or in an healthcare institution. 
METHODS: Cost data was extracted on 293 men from
CaPSURE, a longitudinal disease registry of patients with
PCa. Standard charges (1997 dollars) were applied to all
healthcare services in the last four quarters of life. Not all
patients contributed data to each quarter. Descriptive
and multivariate analyses were used to examine cost dif-
ferences between groups. 
RESULTS: About 63% of patients died in institutions,
while 31% died at home. PCa was the reported cause of
death in 32.8% of cases. After controlling for time pe-
riod, location and cause of death, total medical costs
were lower in the last 3 months of life for PCa patients
who died at home ($1975 versus $3179, p  0.05). No
statistical differences were found in the preceding three
quarters. 
CONCLUSIONS: Total medical costs in the last 3
months of life were lower for PCa patients who die at
home when compared with those dying in healthcare in-
stitutions. Inpatient care costs were nearly three times
higher for patients dying in healthcare institutions. These
cost savings may inform the way we meet the challenge
to improve the quality of life, but also the quality of
death among PCa patients at the end-of-life.
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OBJECTIVE: The economics of the therapy on patients
with stage T1 and T2 prostate carcinoma with the alter-
natives Iodine 125-seed implantation in form of Rapid
Strand, total prostatectomy and beam radiation is the ob-
ject of this study.
METHODS AND RESULTS: The costs are calculated
from the perspective of the health insurance fund, thus
giving only direct costs. For the observed time period of 7
years, allowing for a discount rate of 5%, a therapy with
Iodine 125-seed implantation amounted to a total of DM
3380 direct costs. The total prostatectomy resulted in a
total of DM 15,298 direct costs and beam radiation was
a total of DM 8058 direct costs. In calculating the output
of alternative therapies, the PSA-progression free survival
parameter of the patients was used to define the effective-
ness. Total prostatectomy was given an effectiveness rate
of 71%, for the Iodine 125-seed implantation a rate of
89% was given and for beam radiation a rate of 74.2%
was given. These effectiveness rates were taken from clin-
ical studies. The effectiveness adjusted costs then came to
DM 3798 for Iodine 125-seed implantation, DM 21,547
for prostatectomy, and DM 10,859 for beam radiation
treatment.
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OBJECTIVE: Treatment-related toxicities in head and
neck cancer can result in high costs and treatment delay
or termination. This study evaluated the practice patterns
and costs associated with mucositis and xerostomia, two
common toxicities in head and neck cancer. 
METHODS: Information on treatment practice patterns
for mucositis and severe (grade 2) xerostomia was de-
rived from the literature and 10 expert oncologists. Di-
rect costs (in 1997 US dollars) were estimated for drugs,
administration, laboratory procedures, healthcare visits,
and hospitalization. National cost sources were used for
medical resource use. The treatment time frame for acute
mucositis and xerostomia episodes ranged from 3–7
weeks. Because of the long-term sequelae associated with
severe xerostomia, 1-year costs were also considered in
the cost estimates for this toxicity. Treatment patterns
and costs were examined separately for mild (grades 1–2)
and severe (grades 3–4) mucositis. 
RESULTS: The treatment course for severe xerostomia
included oral saline rinses, pilocarpine, dental and nutri-
tionist visits, and fluoride gel. The cost of these treatments
was $2144 per episode (including 1-year costs); 75% was
attributable to dental care. Treatment for grades 1–2 mu-
cositis included prescription analgesics, oral rinses, PEG
tube placement, nutritional supplements, antifungals, and
physician/nurse visits. The average cost was $913. A
grade 3–4 mucositis episode cost $4543; 72% related to
nutritional complications, including hospitalization. 
CONCLUSION: The results of this study indicate that
the cost of managing mucositis and xerostomia is sub-
stantial. The use of prophylactic cytoprotective agents
should be considered to protect the oral mucosa from
CRT and RT damage, and to minimize resource use.
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OBJECTIVE: Determine the validity and reliability of the
Patient Benefit Questionnaire (PBQ), an 8-item patient
self-report instrument designed to assess xerostomia-
related outcomes in patients (such as radiation treated
head and neck cancer patients) with reduced salivary flow. 
METHODS: The conceptual model, reliability, validity,
responsiveness, and interpretability were evaluated using
the instrument-review criteria developed by the Scientific
Advisory Committee (SAC) of the Medical Outcomes
Trust. Data were collected in a 1-year clinical trial com-
paring amifostine to control in 315 head and neck cancer
patients undergoing radiation therapy. 
RESULTS: Validity of the PBQ was demonstrated by fac-
tor analytic confirmation of the conceptual model. Inter-
nal consistency (Cronbach’s alpha) of 0.78 and test-retest
of 0.87 for the PBQ scale exceeded minimum SAC stan-
dard (0.7) for scale reliability. The PBQ average score
showed acceptable ceiling and floor effects as well as ade-
quate variability. Construct validity was demonstrated by
correlation of the PBQ score in the expected direction
with clinician assessments of xerostomia, mucositis, and
weight change. Responsiveness to change and interpret-
ability of PBQ scores were demonstrated by approxi-
mately a 1-point change in the PBQ score associated, on
average, with a 1-grade change in a clinician-rated xeros-
tomia toxicity score. 
CONCLUSIONS: The 8-item PBQ was found to be a re-
liable, valid and responsive measure to assess xerostomia
outcomes in head and neck cancer patients undergoing
radiotherapy. The PBQ scores were found to be relevant
measures of clinical benefit and interpretable due to the
strong link to xerostomia toxicity scores.
